ASCO 2013--Stage IVs living longer and longer as treatments improve

[Lani]

Abstract only from upcoming asco--her2 not mentioned, probably because data based on SEER results which probably don't record her2 status


Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time?

Sub-category:
ER+

Category:
Breast Cancer - HER2/ER

Meeting:
2013 ASCO Annual Meeting

Abstract No:
524

Citation:
J Clin Oncol 31, 2013 (suppl; abstr 524)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Shaheenah S. Dawood, Benjamin Haaland, Constance T. Albarracin, Ana M. Gonzalez-Angulo, Sudeep Gupta, Javier Cortes, Yoon Sim Yap, Rebecca Dent; Dubai Hospital, Dubai, United Arab Emirates; Duke-National University of Singapore Graduate Medical School, Singapore, Singapore; The University of Texas MD Anderson Cancer Center, Houston, TX; Tata Memorial Centre, Mumbai, India; Vall d'Hebron University Hospital, Barcelona, Spain; National Cancer Centre Singapore, Singapore, Singapore; National Cancer Center Singapore, Duke-National University Singapore, Singapore, Singapore

Abstract Disclosures


Abstract:

Background: Studies have shown a moderate increase in survival over time among pts with stageIV breast cancer. Median survival is approximately 2 yrs. The aim of this study was to evaluate trends over time of pts with synchronous stage IV disease who survive >2 yrs. Methods: Using the SEER registry we identified female pts with synchronous stage IV breast cancer diagnosed between 1990-2007. Pts were divided into 3 groups according to year of diagnosis(1990-1995, 1996-2000, 2001-2007). Probability of surviving more than >2 yrs was computed within each group. A multivariable logistic regression model was then fitted to determine the association between year of diagnosis and the probability of surviving >2 yrs after adjusting for other prognostic factors. Results: 22,492 pts were identified of whom 9,388 (41.7%) had a survival of >2 yrs. The probability of surviving >2 yrs was 36.2%, 40.1%, and 44.2% among pts diagnosed in periods 1990-1995, 1996-2000, and 2001-2007 respectively (p-value < 0.0001). The probability of surviving >2 yrs was 55.3% and 29.3% among pts with ER+ and ER- disease respectively (p-value <0.0001) and was 32.9% and 43.5% among pts of black and white race respectively (p-value <0.0001). In the multivariable model the probability of surviving >2 yrs increased with increasing year of diagnosis (OR 1.04, 95% CI 1.03-1.05, p <0.0001). Other factors significantly associated with an increased probability of surviving >2 yrs included radiation therapy, lower grade, younger age, hormone receptor (HR) positive disease and non-inflammatory disease. Interaction term between race and year of diagnosis was marginally significant, such that black pts had a more slowly increasing probability of surviving >2 yrs compared to whites (OR 0.97, 95% CI 0.96-1.00, p = 0.037). Interaction term between HR status and year of diagnosis was not significant. Conclusions: Our results indicate that among pts with synchronous stage IV breast cancer the probability of surviving >2 yrs has increased over time reflecting the introduction and FDA approval of multiple efficacious chemotherapeutic and endocrine therapeutic options. Of concern, the probability of surviving >2 yrs has increased more slowly among pts of black race.